129 related articles for article (PubMed ID: 12077885)
1. [Does collaboration inside the European Union improve Finnish drug safety?].
Palva E
Duodecim; 2000; 116(24):2810-1. PubMed ID: 12077885
[No Abstract] [Full Text] [Related]
2. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
Ainsworth MA
Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
[TBL] [Abstract][Full Text] [Related]
3. [Experiences of the drug approval processes in the European Union].
Pasanen M; Toivonen M
Duodecim; 2000; 116(24):2817-22. PubMed ID: 12077887
[No Abstract] [Full Text] [Related]
4. [Marketing of pediatric drugs].
Pabst JY
Soins Pediatr Pueric; 2003; (210):18-9. PubMed ID: 12683130
[No Abstract] [Full Text] [Related]
5. [The role of the Danish Medical Products Agency in clinical trials].
Simonsen AC
Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
[TBL] [Abstract][Full Text] [Related]
6. Beware of new drugs, study suggests.
Levenson D
Rep Med Guidel Outcomes Res; 2002 May; 13(10):1-2, 5. PubMed ID: 12492085
[No Abstract] [Full Text] [Related]
7. Making the most of spontaneous adverse drug reaction reporting.
Waller PC
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):320-3. PubMed ID: 16611209
[TBL] [Abstract][Full Text] [Related]
8. Drug safety--important to us all!
Böttiger LE
J Intern Med; 2001 Oct; 250(4):269-70. PubMed ID: 11576314
[No Abstract] [Full Text] [Related]
9. [European network for investigation of medicinal products in children (Medichildren)].
Pons G
Arch Pediatr; 2006 Jun; 13(6):631. PubMed ID: 16713209
[No Abstract] [Full Text] [Related]
10. Drug evaluation and approval process in the European Union.
San Miguel MT; Vargas E
Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
[No Abstract] [Full Text] [Related]
11. [Sweden can contribute to safer drug assessment].
Strandberg K
Lakartidningen; 2006 Jun 8-13; 103(23):1853-5. PubMed ID: 16838598
[No Abstract] [Full Text] [Related]
12. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
[TBL] [Abstract][Full Text] [Related]
13. [Network for investigation of medicinal products in children].
Kassaï B; Treluyer JM; Jacqz-Aigrain E; Pons G
Arch Pediatr; 2006 Jun; 13(6):631-4. PubMed ID: 16697606
[No Abstract] [Full Text] [Related]
14. [A regional center for reporting adverse drug reactions in Umeå. Prompt handling results in quick feedback].
Bäckström M; Dahlqvist R; Mjörndal T; Spigset O; Hedenmalm K; Granberg K; Oqvist U; Wiholm BE
Lakartidningen; 1995 Jan; 92(3):148-50. PubMed ID: 7837847
[No Abstract] [Full Text] [Related]
15. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
16. Synthesising licensing data to assess drug safety.
McPherson K; Hemminki E
BMJ; 2004 Feb; 328(7438):518-20. PubMed ID: 14988197
[TBL] [Abstract][Full Text] [Related]
17. Are novel drugs more risky for patients than less novel drugs?
Olson MK
J Health Econ; 2004 Nov; 23(6):1135-58. PubMed ID: 15556240
[TBL] [Abstract][Full Text] [Related]
18. [Opinion survey of European pharmacovigilance: opinion of French practitioners].
Pierfitte C; Hanesse B; Royer RJ
Therapie; 1995; 50(2):171-2. PubMed ID: 7631296
[No Abstract] [Full Text] [Related]
19. European pharmacovigilance: an overview of pharmacovigilance inspections.
Koster MC; van den Oetelaar AH
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):711-3. PubMed ID: 16142691
[No Abstract] [Full Text] [Related]
20. International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Jul; 66(135):36791-2. PubMed ID: 12356097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
